Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Unii-15z7208b52
2. Unii-231982l46k
3. Collagenase (clostridium Histolyticum Gene Colh Isoenzyme Aux-ii)
4. 955089-04-0
5. 955089-06-2
6. 15z7208b52
7. 231982l46k
Molecular Weight | 80.16 g/mol |
---|---|
Molecular Formula | Ca2+4 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 0 |
Rotatable Bond Count | 0 |
Exact Mass | 79.9251817 g/mol |
Monoisotopic Mass | 79.9251817 g/mol |
Topological Polar Surface Area | 0 Ų |
Heavy Atom Count | 2 |
Formal Charge | 4 |
Complexity | 0 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Details:
The companies will merge and integrate their entire pipelines, including Xiaflex (collagenase clostridium histolyticum) for treating adult patients with Dupuytren’s contracture.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Musculoskeletal Brand Name: Xiaflex
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Mallinckrodt Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 13, 2025
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Mallinckrodt Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Mallinckrodt and Endo Get a Bump from Tariffs in $6.7 Billion Merger
Details : The companies will merge and integrate their entire pipelines, including Xiaflex (collagenase clostridium histolyticum) for treating adult patients with Dupuytren’s contracture.
Product Name : Xiaflex
Product Type : Enzyme
Upfront Cash : Undisclosed
March 13, 2025
Details:
Xiaflex (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is indicated for Dupuytren's Contracture treatment.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Xiaflex
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2025
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo to Present Peyronie’s Disease Findings at Urological Association Meeting
Details : Xiaflex (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is indicated for Dupuytren's Contracture treatment.
Product Name : Xiaflex
Product Type : Enzyme
Upfront Cash : Inapplicable
March 12, 2025
Details:
Xiaflex (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is indicated for Dupuytren's Contracture treatment.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Musculoskeletal Brand Name: Xiaflex
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2024
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
John Elway Partners with Endo to Promote XIAFLEX® for Dupuytren's Contracture
Details : Xiaflex (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is indicated for Dupuytren's Contracture treatment.
Product Name : Xiaflex
Product Type : Enzyme
Upfront Cash : Inapplicable
November 20, 2024
Details:
EN3835 (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is being investigated for plantar fibromatosis.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Rare Diseases and Disorders Brand Name: Qwo
Study Phase: Phase IIIProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2023
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EN3835 (collagenase clostridium histolyticum) is a collagenase enzyme used to promote debridement of necrotic tissue in burns and skin ulcers. It is being investigated for plantar fibromatosis.
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
March 13, 2023
Details:
Qwo® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable is used for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is contraindicated in patients with a history of hypersensitivity to collagenase.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Qwo
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 10, 2022
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society f...
Details : Qwo® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable is used for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is contraindicated in patients with a history of hypersensitivity to collagenase.
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
July 10, 2022
Details:
Qwo (collagenase clostridium histolyticum-aaes), is a prescription medicine used to treat moderate to severe cellulite in the buttocks of adult women, may cause serious side effects including allergic.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Qwo
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2022
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aae...
Details : Qwo (collagenase clostridium histolyticum-aaes), is a prescription medicine used to treat moderate to severe cellulite in the buttocks of adult women, may cause serious side effects including allergic.
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
May 05, 2022
Details:
Phase 2 study participants receiving up to 3 doses of Xiaflex (collagenase clostridium histolyticum) showed improvement in change from baseline ifor affected shoulder at Day 95, compared to those study participants receiving placebo was not significant.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Musculoskeletal Brand Name: Qwo
Study Phase: Phase IIProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2022
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2 study participants receiving up to 3 doses of Xiaflex (collagenase clostridium histolyticum) showed improvement in change from baseline ifor affected shoulder at Day 95, compared to those study participants receiving placebo was not significant.
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
January 07, 2022
Details:
Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Xiaflex
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2020
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Endo to Present Qwo™ (Collagenase Clostridium Histolyticum-Aaes) Data at Vegas Cosmetic Surgery ...
Details : Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.
Product Name : Xiaflex
Product Type : Enzyme
Upfront Cash : Inapplicable
September 24, 2020
Details:
Endo International will present data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during the American Society for Dermatologic Surgery's Annual Meeting.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Qwo
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 10, 2020
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Endo International will present data relevant to the use of Endo Aesthetics' Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women during the American Society for Dermatologic ...
Product Name : Qwo
Product Type : Enzyme
Upfront Cash : Inapplicable
September 10, 2020
Details:
BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Brand Name: Xiaflex
Study Phase: Approved FDFProduct Type: Enzyme
Sponsor: Endo Pharm
Deal Size: $540.0 million Upfront Cash: $540.0 million
Deal Type: Acquisition February 12, 2020
Lead Product(s) : Collagenase Clostridium Histolyticum
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Endo Pharm
Deal Size : $540.0 million
Deal Type : Acquisition
Endo Completes Acquisition of BioSpecifics
Details : BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.
Product Name : Xiaflex
Product Type : Enzyme
Upfront Cash : $540.0 million
February 12, 2020
RLD :
TE Code :
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Brand Name : XIAFLEX
Dosage Form : SOLUTION; INJECTION
Dosage Strength : 0.9MG
Approval Date :
Application Number : 125338
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES
Brand Name : QWO
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 0.92MG/VIAL
Approval Date :
Application Number : 761146
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES
Brand Name : QWO
Dosage Form : SOLUTION;SUBCUTANEOUS
Dosage Strength : 1.84MG/VIAL
Approval Date :
Application Number : 761146
RX/OTC/DISCN :
RLD :
TE Code :
Regulatory Info :
Registration Country : Norway
Collagenase Clostridium Histolyticum
Brand Name : Xiapex
Dosage Form : Powder and liquid to the injection fluid, resolution
Dosage Strength : 0.9 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Collagenase Clostridium Histolyticum; Chloramphenicol
Brand Name : Iruxol
Dosage Form :
Dosage Strength : Pom Derm 30 G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Sweden
collagenase clostridium histolyticum
Brand Name : Xiapex
Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Dosage Strength : 0.9 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Collagenase Clostridium Histolyticum
Brand Name : Xiapex
Dosage Form : Collagenase Clostridium Histolyticum 0,9Mg 1 Units Use Intralesional
Dosage Strength : 1 vial groun 0.9 mg + 1 vial solv
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Collagenase Clostridium Histolyticum
Brand Name : Xiapex
Dosage Form : Powder and liquid to the injection fluid, resolution
Dosage Strength : 0.9 mg
Packaging : Hood glass
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : Generic
Registration Country : Turkey
Glucosamine Sulphate Potassium Chloride; Chondroitin Sulfate A; Collagenase Clostridium Histolyticum; Cucurmin; Fennel; eucalyptol; Clove Oil; Menthol
Brand Name : Arteasy
Dosage Form : CREAM
Dosage Strength :
Packaging : 50 ML
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
63
PharmaCompass offers a list of Collagenase Clostridium Histolyticum API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Collagenase Clostridium Histolyticum manufacturer or Collagenase Clostridium Histolyticum supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Collagenase Clostridium Histolyticum manufacturer or Collagenase Clostridium Histolyticum supplier.
PharmaCompass also assists you with knowing the Collagenase Clostridium Histolyticum API Price utilized in the formulation of products. Collagenase Clostridium Histolyticum API Price is not always fixed or binding as the Collagenase Clostridium Histolyticum Price is obtained through a variety of data sources. The Collagenase Clostridium Histolyticum Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Collagenase Clostridium Histolyticum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Collagenase Clostridium Histolyticum, including repackagers and relabelers. The FDA regulates Collagenase Clostridium Histolyticum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Collagenase Clostridium Histolyticum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Collagenase Clostridium Histolyticum supplier is an individual or a company that provides Collagenase Clostridium Histolyticum active pharmaceutical ingredient (API) or Collagenase Clostridium Histolyticum finished formulations upon request. The Collagenase Clostridium Histolyticum suppliers may include Collagenase Clostridium Histolyticum API manufacturers, exporters, distributors and traders.
click here to find a list of Collagenase Clostridium Histolyticum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Collagenase Clostridium Histolyticum as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Collagenase Clostridium Histolyticum API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Collagenase Clostridium Histolyticum as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Collagenase Clostridium Histolyticum and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Collagenase Clostridium Histolyticum NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Collagenase Clostridium Histolyticum suppliers with NDC on PharmaCompass.
Collagenase Clostridium Histolyticum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Collagenase Clostridium Histolyticum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Collagenase Clostridium Histolyticum GMP manufacturer or Collagenase Clostridium Histolyticum GMP API supplier for your needs.
A Collagenase Clostridium Histolyticum CoA (Certificate of Analysis) is a formal document that attests to Collagenase Clostridium Histolyticum's compliance with Collagenase Clostridium Histolyticum specifications and serves as a tool for batch-level quality control.
Collagenase Clostridium Histolyticum CoA mostly includes findings from lab analyses of a specific batch. For each Collagenase Clostridium Histolyticum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Collagenase Clostridium Histolyticum may be tested according to a variety of international standards, such as European Pharmacopoeia (Collagenase Clostridium Histolyticum EP), Collagenase Clostridium Histolyticum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Collagenase Clostridium Histolyticum USP).